$1.45
1.40% yesterday
Nasdaq, Nov 25, 10:00 pm CET
ISIN
US23255M1053
Symbol
CYCN
Sector
Industry

Cyclerion Therapeutics,Inc. Stock price

$1.45
-1.58 52.15% 1M
-1.51 51.01% 6M
-1.90 56.72% YTD
-0.46 24.08% 1Y
-51.55 97.26% 3Y
-37.95 96.32% 5Y
-248.55 99.42% 10Y
Nasdaq, Closing price Mon, Nov 25 2024
+0.02 1.40%
ISIN
US23255M1053
Symbol
CYCN
Sector
Industry

Key metrics

Market capitalization $3.93m
Enterprise Value $1.06m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 5.58
P/S ratio (TTM) P/S ratio 20.68
P/B ratio (TTM) P/B ratio 0.45
Revenue growth (TTM) Revenue growth -68.09%
Revenue (TTM) Revenue $190.00k
EBIT (operating result TTM) EBIT $-5.93m
Free Cash Flow (TTM) Free Cash Flow $-6.23m
Cash position $2.87m
EPS (TTM) EPS $-2.12
Short interest 0.87%
Show more

Is Cyclerion Therapeutics,Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

Cyclerion Therapeutics,Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Cyclerion Therapeutics,Inc.:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast Cyclerion Therapeutics,Inc.:

Buy
100%

Financial data from Cyclerion Therapeutics,Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
0.19 0.19
69% 69%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 5.87 5.87
52% 52%
3,089%
- Research and Development Expense 0.25 0.25
97% 97%
132%
-5.93 -5.93
72% 72%
-3,121%
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -5.93 -5.93
72% 72%
-3,118%
Net Profit -5.28 -5.28
80% 80%
-2,779%

In millions USD.

Don't miss a Thing! We will send you all news about Cyclerion Therapeutics,Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Cyclerion Therapeutics,Inc. Stock News

Neutral
GlobeNewsWire
4 months ago
CAMBRIDGE, Mass., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), today announced that Regina Graul, Ph.D.

Company Profile

Cyclerion Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of treatments for serious and orphan diseases, through the use of soluble guanylate cyclase (sGC) pharmacology. Its product pipeline includes several sGC stimulators, a small molecules that act synergistically with nitric oxide on sGC to boost production of cyclic guanosine monophosphate (cGMP). The company was founded on September 6, 2018 and is headquartered in Cambridge, MA.

Head office United States
CEO Regina Graul
Employees 1
Founded 2018
Website www.cyclerion.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today